Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
2019; Massachusetts Medical Society; Volume: 380; Issue: 18 Linguagem: Inglês
10.1056/nejmoa1817226
ISSN1533-4406
AutoresNoopur Raje, Jesús G. Berdeja, Yi Lin, David S. Siegel, Sundar Jagannath, Deepu Madduri, Michaela Liedtke, Jacalyn Rosenblatt, Marcela V. Maus, Ashley Turka, Lyh-Ping Lam, Richard A. Morgan, Kevin M. Friedman, Monica Massaro, Julie Wang, Greg Russotti, Zhihong Yang, Timothy Campbell, Kristen Hege, Fabio Petrocca, M. Travis Quigley, Nikhil C. Munshi, James N. Kochenderfer,
Tópico(s)Nanowire Synthesis and Applications
ResumoPreclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.
Referência(s)